Merck, Inc.

🇵🇭Philippines

Country: 🇵🇭Philippines

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

Phase 3

Completed

Conditions: Herpes Zoster
Pneumococcal Infection

Interventions: Biological: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
Biological: Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23

First Posted Date: 2007-09-26

Last Posted Date: 2017-04-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 473

Registration Number: NCT00535730

A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)

Phase 1

Completed

Conditions: Herpes Zoster-related Complications
Herpes Zoster

Interventions: Biological: Placebo
Biological: V212

First Posted Date: 2007-09-26

Last Posted Date: 2019-05-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 341

Registration Number: NCT00535236

Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

Phase 4

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Pataday
Drug: Elestat

First Posted Date: 2007-09-26

Last Posted Date: 2015-05-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 79

Registration Number: NCT00534794

Locations: 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Phase 3

Completed

Conditions: Shingles

Interventions: Biological: Zoster Vaccine, Live (Zostavax™)

First Posted Date: 2007-09-24

Last Posted Date: 2017-04-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 22439

Registration Number: NCT00534248

Endpoint Validation Study (0524A-015)

Phase 2

Completed

Conditions: Flushing

First Posted Date: 2007-09-21

Last Posted Date: 2017-02-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 165

Registration Number: NCT00533676

Effect of MK0524A on Flushing Caused by Niacin (0524A-056)

Phase 3

Completed

Conditions: Flushing

First Posted Date: 2007-09-21

Last Posted Date: 2017-02-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 330

Registration Number: NCT00533611

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Phase 2

Completed

Conditions: Post-Menopausal Osteoporosis

First Posted Date: 2007-09-21

Last Posted Date: 2016-07-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 227

Registration Number: NCT00533650

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: sitagliptin phosphate (+) metformin hydrochloride

First Posted Date: 2007-09-21

Last Posted Date: 2017-06-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 517

Registration Number: NCT00532935

MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Phase 2

Completed

Conditions: Hypercholesterolemia

First Posted Date: 2007-09-21

Last Posted Date: 2017-04-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 407

Registration Number: NCT00533312

MK0686 in Postsurgery Dental Pain (0686-002)

Phase 2

Completed

Conditions: Pain, Postoperative

First Posted Date: 2007-09-21

Last Posted Date: 2015-06-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 114

Registration Number: NCT00533403

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy